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Cell Migration and Chimerism-A Unifying Concept in 
Transplantation-With Particular Reference to HLA Matching and 
Tolerance Induction 
T.E. Starzl 
WE recently reported that the acceptance of whole-
organ transplants connotes (and requires) a special 
kind of mixed chimerism involving an exchange between 
organ and recipient oflymphodendritic leukocytes (Fig 1 ).1 
The consequence in five of five patients studied 27 to 29V2 
years after kidney transplantation from HLA-mismatched 
donors was the diffuse presence of donor dendritic cells in 
the lymph nodes and skin of the recipient. 2 Chronically 
surviving liver recipients have even more prominent evi-
dence of systemic and graft chimerism,I.3 which can be 
shown with immunocytochemical techniques and con-
firmed with polymerase chain reaction (PCR) technology. 
Chimerism has been particularly easy to study after intes-
tinal transplantation.4.5 
With the thesis that this cell migration, repopulation, 
and consequent chimerism is the basis of graft acceptance, 
no matter what the organ transplanted, I we are able to 
reexamine some controversies in transplantation immunol-
ogy, including why HLA tissue matching to govern the 
distribution of cadaveric organs has been so nonpredictive 
of outcome. To understand these controversies, we must 
turn back the pages 50 years, when Peter Medawar planted 
the seed of our specialty. 
FOUNDATION OF TRANSPLANTATION 
If rejection was an immunologic response, as Medawar 
claimed,o what could be more logical in preventing it than 
to weaken the immune system? By 1951, Medawar (with 
Billingham and Krohnf and the American Morgan8 had 
taken this crucial step and had shown that skin graft 
survival was prolonged with cortisone acetate and adreno-
corticotrophic honnone, the first immunosuppressive 
drugs. The year before, Dempster of Hammersmith 
showed mitigation of skin graft rejection with total body 
irradiation. 9 
These were seemingly small steps, but then Billingham, 
Brent. and Medawar10 raised expectations to a new level 
by showing the possibility of acquiring immunologic toler-
ance, albeit only under the special circumstance of inocu-
lation of immunocompetent adult spleen cells into fetal and 
perinatal mice. Main and Prehn ll were able to mimic these 
conditions of ontogenesis in adult mice using supralethal 
total body irradiation and bone marrow alloreconstitution. 
When the reconstituted mice were shown to be tolerant to 
8 
donor strain skin, the clinical possibility of creating radia-
tion bone marrow chimeras as a means to the end of solid 
organ transplantation seemed obvious. These hopes were 
promptly dashed when the concept of graft-versus-host 
disease (GVHD) and runt disease was delineated by Bill-
il\gham and Brent. 12 
However what was not clearly recognized then or later 
was that these whole-animal models and the subsequently 
exploited FI hybrid model were almost artifacts in that the 
interactions of the two-way cell migration and repopula-
tion shown in Fig 1 were precluded (I) by the immature 
state of one party (the Billingham, Brent, Medawar mod-
el), (2) by the cytoablation used by Main and Prehn (and 
later bone marrow transplanters). or (3) by genetic manip-
ulation (the F 1 hybrid model). These were whole animal 
analogues of the one-way, mixed-lymphocyte reaction 
(MLR) introduced much later by Bain, Vas, and Lowen-
stein et al 13 and Bach and Hirschhorn. 14 
The precision of the one-way systems allowed easy 
interpretation of the results and invariably showed an 
almost perfect correlation between histocompatibility and 
the immune reaction of the target lymphocytes, whether 
these were in vitro or in vivo. Now that we know about cell 
migration and repopulation, it seems likely that the rele-
vant in vitro (or surrogate) model of clinical transplanta-
tion for at least some purposes should be the two-way 
MLR, in which the effect of two cell populations-each on 
the other-can be studied. 
DIVISION OF THE FIELD 
Of course, this is hindsight 33 years later. Between 1959 
and 1963-and without really knowing why-the intellec-
tual root that came from Medawar's seed divided into two 
branches that soon looked like separate trees (Fig 2). The 
differences between the branches actually reflected diver-
gent therapeutic dogmas. The bone marrow tree with its 
precondition of cytoablation mimicked the Billingham, 
From the Department of Surgery, University of Pittsburgh, 
Pennsylvania. 
Address reprint requests to Dr Thomas E. Starzl, Department of 
Surgery, 3601 Fifth Ave, Falk Clinic, Pittsburgh, PA 15213. 
© 1993 by Appleton & Lange 
0041·1345/931$3.001 +0 
Transplantation Proceedings, Vol 25, No 1 (February), 1993: pp 8-12 
• 
I 
PRESIDENTIAL ADDRESS 
,., 
• 
• • • • ,
, 
Fig 1. Systemic and graft chimerism after kidney transplantation. 
Brent. and Medawar model and was the in vivo version of 
a one-way MLR. HLA matching was crucial. Engraftment 
in a drug-free state (called tolerance) was a realizable 
objective with perfect matching, although this was not 
achieved clinically until 1968. 15 • 16 However, even with 
MHC compatibility. GVHD was a constant threat. 
The reason for the virulence of GVHD with an HLA 
mismatch was the complete removal of a counterweight to 
the transplanted immunocytes, as shown in Fig 3 in which 
each of the six antigens (two each at the A. B. and D loci) 
has been given equal importance. With perfect matching, 
immune modulation usually could control non-MHC reac-
tions responsible for GVHD and/or rejection and keep the 
donor-recipient immunologic teeter-totter in balance. This 
was not possible with significantly mismatched donors. 
The whole-organ transplanters who had broken ranks 
with their bone marrow colleagues (Fig 2) empirically 
developed long-term immunosuppression with which suc-
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Fig 2. Division of transplantation into whole-organ and bone 
marrow camps. 
cess (called graft acceptance. not tolerance) did not de-
pend on matching and could be accomplished without 
GVHD, even after the transplantation of lymphoid-rich 
organs such as the intestine and liver. 17•18 
The explanation for the GVHD resistance with whole 
organs is envisioned as the interaction of cells coming out 
from the allograft with the immunocytes of the recipient (a 
two-way MLR) (Fig 4). However, if this whole-organ 
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Fig 3. In vivo one-way MlR with recipient cytoablation or with the 
F, hybrid experimental model. 
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Fig 4. Donor-recipient cell interaction with two-way MLR in vitro 
or in vivo. 
system is immunologically unbalanced by cytoablation or, 
as in the cross-back F 1 hybrid model. used in the classical 
intestinal transplant studies of Monchik and Russell,I9 a 
lymphoid-rich graft, such as the intestine. will eat the 
recipient alive with an uncontrolled GVHD (Fig 5). 
With bone marrow transplantation also, avoidance of 
GVHD when the recipient system is left at least partially 
intact was recognized (and strongly emphasized) by Slavin 
and Strober in the 1970s.20 and demonstrated even more 
clearly in the brilliant studies of Ildstad and Sachs,21 who 
concocted various mixtures of donor and recipient bone 
marrow cells ex vivo and then systematically created 
mixed allogeneic chimeras by infusing the mixtures into 
cytoablated recipients who did not develop GVHD. 
DILUTION OF HISTOCOMPATIBILITY 
Of course. the fact that mixed chimerism interdicts GVHD 
is only half the story. The other half is that the donor-
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Fig 5. Inevitability of GVHD with unbalanced system. 
STARZL 
G V H 
t 
HVG (Rejection) 
Fig 6. Natural imbalance between the Iymphodendritic poor 
kidney and the recipient. 
recipient cell interaction (which we have called mutual 
natural immunosuppression) also mitigates the host-ver-
sus-graft reaction (rejection). In Fig 6, we have depicted a 
kidney with its relatively small leukocyte army. As was 
recently proved in recipients examined after they had 
borne transplanted kidneys for nearly 30 years,2 remnants 
of this army remain identifiable in recipient tissues for the 
lifetime of the graft. 1.2 The details of this donor-recipient 
rapprochement are not known, but it seems clear that even 
organs with a poor lymphoreticular constituency have 
enough dendritic cells to induce for themselves the donor-
specific nonreactivity that is called tolerance. 
This was demonstrated in our long-surviving kidney 
recipients2 and in studies reported from Stanford by 
Strober et al22 in patients treated with total lymphoid 
irradiation and a short course of antilymphocyte globulin. 
The donor-recipient interactions are envisioned as occur-
ring on a sliding scale in which each further level of 
histoincompatibility provokes countervailing although not 
equal increases in the mutually cancelling donor-versus-
recipient and recipient-versus-donor cell reactivity (Fig 7). 
Case by case individualization of immunosuppression for 
variable periods of time. or often permanently, is required 
to affect a harmonious balance between the cell systems. 
With this concept, it becomes possible to understand 
why Terasaki23 and others have shown such a small 
advantage even for six-antigen-matched cadaver kidney 
allografts and essentially none for lesser degrees of match-
ing. Most importantly, it becomes possible to understand 
why so many recipients of unmatched kidneys do well 
even as debates rage about a few percentage points that 
may be gained or lost by matching or failure to do so. For 
livers, the strange reports from Cambridge24 and Pitts-
burgh25 become comprehensible that have shown an in-
verse relation between tissue matching and survival of 
liver recipients. but again with a matching influence that 
does not exceed a few percentage points. 
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Fig 7. Cancelling of histocompatibility matching effect by donor-
recipient cell interaction shown in Figs 4 and 6. 
AUGMENTING TOLEROGENICITY 
It seems obvious that the crucial variable distinguishing 
one organ from another is the lymphodendritic (not the 
parenchymal) component of whole-organ grafts. and that 
these leukocytes can be tolerogenic as well as immuno-
genic when effective immunosuppression is given. Be-
Fig 8. Rank order tolerogenicity of major organs correlates with 
Iymphodendritic constituency. 
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Fig 9. Augmentation of tolerogenic cells for "underprivileged" 
organs such as heart and kidney by concomitant bone marrow 
infusion. 
cause of its dense constituency of these cells. the liver is 
high on the favorable list of tolerogenicity with the lung 
and intestine following and the heart and kidney bringing 
up the rear (Fig 8). It is self-evident that the underprivi-
leged kidney and heart could be brought to the same level 
of tolerogenicity advantage as the liver by the periopera-
tive infusion of lymphoreticular cells obtained from bone 
marrow of the organ donor (Fig 9) or possibly from the 
spleen. 
Now the cycle is complete because this was the starting 
point for Billingham. Brent. and Medawar.lo and then 
Main and Prehn. II It would be particularly unjust not to 
mention that such cell supplementation with bone marrow 
for whole-organ transplantation is what our ex-President 
Monaco has been advocating for more than 20 years,26 
leading to a major clinical trial by Barber and Diethelm in 
Alabama. z7 
(Medawar) 
Fig 10. Reconciliation of whole-organ and cell transplanters. 
---------------------
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CONCLUSIONS 
With the cell migration concept, the framework given to us 
by Billingham, Brent, and Medawar is considerably ex-
panded and provides immediate clinical applications, such 
as a better understanding of why HLA matching is not 
more discriminating for whole organ allocation, and how to 
induce tolerance. This means a reunification is inevitable 
of the long-separated interests and ideologies of bone 
marrow and solid organ transplantation (Fig 10). These are 
the directions that our Society will be taking. Medawar 
would smile if he could come back for just one day to hear 
this. At least we still can report these things directly to our 
friends, Billingham and Brent. 
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